ArticleMolecular and clinical oncology2019

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature.

Arsela Prelaj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.